TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02251301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skim Milk
Description: 250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High intensity interval training
Description: All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
Study: NCT02251301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
Study: NCT02655263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone bodies
Description: ketone bodies infusion
Study: NCT01478230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine 5 mg Inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine 10 mg Inhaler
Study: NCT03397888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: 80 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: 80 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: 80 mg capsule
Study: NCT03663127

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beauty Drink
Description: Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
Study: NCT03836430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newborn Behavioral Observation-Family Wellness (NBO-FW)
Description: The intervention has been described in the arm description.
Study: NCT01904149

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo single oral dose (first 8 hours)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo single oral dose (first 8 hours)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo single oral dose (first 8 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-single dose
Description: Dexketoprofen single oral dose (first 8 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol-single dose
Description: Tramadol single oral dose (first 8 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Tramadol-single dose
Description: Dexketoprofen/Tramadol single oral dose (first 8 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-multiple doses
Description: Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Dexketoprofen-multiple doses
Description: Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol-multiple doses
Description: Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol-multiple doses
Description: Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Tramadol-multiple doses
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Dexketoprofen/Tramadol-multiple doses
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
Study: NCT00838825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: introduction of the chronic care model
Description: The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
Study: NCT01641146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sexual Health Intervention for Men (ES-HIM)
Description: ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion (HP) Comparison Arm
Description: Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
Study: NCT04326725

Intervention type: DRUG
Intervention: Plaquenil 200Mg Tablet
Description: health workers under risk who took this medications
Study: NCT02227173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study: NCT01452230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical activity
Description: Supervised physical activity
Study: NCT03404804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
Study: NCT04350671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose of Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose of Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study: NCT00711347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DisCoVisc
Description: Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon5
Description: Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
Study: NCT00823992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc once weekly for 4 weeks, then 20mg sc once weekly
Study: NCT02636244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE Gel
Study: NCT01655043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadofoveset trisodium
Description: All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
Study: NCT02251301

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Macronutrient isoenergetic control
Description: 250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
Study: NCT03765658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT0151Y dose escalation
Description: Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
Study: NCT01825720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Glucose-Insulin-Potassium)GIK group
Description: infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline group
Description: same rate of normal saline
Study: NCT03385759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental knee arthroplasty
Description: Implant to replace the medial compartment of a patient with knee osteoarthritis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Implant to replace the knee joint of a patient with knee osteoarthritis
Study: NCT02399241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bluetooth enabled nebuliser device (I-neb)
Study: NCT00570999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 mg/kg/day
Study: NCT02229214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia
Study: NCT00570999

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1,2 mL once daily
Study: NCT03224806

Intervention type: OTHER
Group type: OTHER
Intervention: Wholegrain bread
Description: 156.8g wholegrain bread

Intervention type: OTHER
Group type: OTHER
Intervention: White bread
Description: 122.6g white bread

Intervention type: OTHER
Group type: OTHER
Intervention: 15% fiber-rich bread
Description: 139.2g bread made with 15% added wheat bran

Intervention type: OTHER
Group type: OTHER
Intervention: 30% fiber-rich bread
Description: 166.5g bread made with 30% added wheat bran
Study: NCT02229214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01080768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine
Description: Aliskiren/amlodipine 150/5 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Aliskiren/amlodipine
Description: Placebo to Aliskiren/amlodipine 150/10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Amlodipine
Description: Placebo to Amlodipine 5 mg/day
Study: NCT00975104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 745 0.3 mg/kg
Description: AMG 745 0.3 mg/kg IV QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 745 1.0 mg/kg
Description: AMG 745 1.0 mg/kg IV QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 745 3.0 mg/kg
Description: AMG 745 3.0 mg/kg IV QW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV QW
Study: NCT02386098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: HIV Maturation Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: HIV Maturation Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: HIV Maturation Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Description: Atazanavir

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir (ATV)
Description: Atazanavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Description: Atazanavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Description: Atazanavir

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir (ATV)
Description: Atazanavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: Ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir (RTV)
Description: Ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir (RTV)
Description: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Dolutegravir

Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir (DTG)
Description: Dolutegravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Dolutegravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Dolutegravir

Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir (DTG)
Description: Dolutegravir

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir (TDF)
Description: Tenofovir

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir (TDF)
Description: Tenofovir
Study: NCT04037020

Intervention type: OTHER
Intervention: Chocolate
Description: Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
Study: NCT01331772

Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Dietetic follow-up only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention arm
Description: Dietetic follow up + adapted physical activity
Study: NCT04555668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation Program
Description: Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring Stretch Program
Description: Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
Study: NCT01920126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: 0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00509756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FXR-450
Description: capsule, single oral doses from 10 mg to 450 mg
Study: NCT01252550

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Activia® (125g/pot)
Description: Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
Study: NCT00509756

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule similar to active drug
Study: NCT04703907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular stimulation
Description: Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)
Study: NCT03865004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol+Morphine
Description: 1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol+Morphine
Description: 1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol+Morphine
Description: 1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen plus Morphine
Description: Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen plus Morphine
Description: Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexketoprofen plus Morphine
Description: Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Morphine
Description: 100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Morphine
Description: 100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Morphine
Description: 100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
Study: NCT02268240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
Study: NCT03693807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic pump and Codman catheter
Description: All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: Please see Detailed Description.
Study: NCT01252550

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acidified non-fermented dairy product
Description: Acidified non-fermented dairy product (125g/pot)
Study: NCT00559468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
Study: NCT03693807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Please see Detailed Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR (Panitumumab or Cetuximab)
Description: Please see Detailed Description.
Study: NCT06195345

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Imaging
Description: MR imaging pertaining to the patient and project (ICHOR 1)
Study: NCT03794232

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NIUCHANG

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo